Mul-1867

June 15, 2016June 15, 2016

TGV-inhalonix Presents Early Data on Drug to Treat Acute Lung Infections in CF Patients

Cystic Fibrosis, News

TGV-inhalonix, Inc., presented data on the drug candidate, Mul-1867, to treat antibiotic-resistant lung infections that is showing promise with the mixed bacterial and fungal infections found in cystic fibrosis (CF) patients. The presentation, from an animal ... Read more

April 15, 2016April 15, 2016

Antimicrobial Agent Targeting Resistant CF Infections Named ‘Orphan Drug’ by FDA

Cystic Fibrosis, News

TGV-Inhalonix, Inc., recently announced that its drug candidate, the antimicrobial agent Mul-1867, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of antibiotic-resistant bacterial ... Read more

February 1, 2016February 3, 2016

Promising Drug Candidate Tackles Wide Variety of Antibiotic-Resistant Infections

Cystic Fibrosis, News, Pneumonia

New York City-based pharma company TGV-Laboratories recently presented a promising compound, Mul-1867, for the treatment of several antibiotic-resistant fungal and bacterial infections – a growing problem that has been estimated to take ... Read more